A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Paclitaxel; Trastuzumab
- Indications Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms GeparQuinto
- 23 May 2018 Results (n=2600) assessing the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab, were published in the Journal of Clinical Oncology.
- 15 Mar 2018 Primary endpoint (To compare the pCR rates of neoadjuvant treatment in Setting III) has not been met as per the results published in the Journal of Clinical Oncology.
- 15 Mar 2018 Results (n=620) assessing long term outcomes in patients with HER2-positive tumors published in the Journal of Clinical Oncology